Skip to content

Insider · CIK 0001395781

Luis Malave

director

Files at GCTK (Glucotrack, Inc.). First filing -, latest -.

Luis Malave files SEC Form 4 as director at GCTK (Glucotrack, Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.

A track record needs three past buys with six months of prices behind them; Luis Malave has 0, so none is measured yet.

Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold

Signals

This insider’s open-market buys and sells, scored.

No scored open-market trades yet.

Transactions

Every row this insider has filed, 21 in all, newest first.

DateCompanyTransactionSharesPriceValueHoldings afterFiled
Mar 25, 2025GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+35$0.00$02,395Oct 7, 2025
Jul 11, 2025GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+1,200$0.00$03,595Oct 7, 2025
Oct 3, 2025GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+463$0.00$04,058Oct 7, 2025
Oct 3, 2025GCTK
Glucotrack, Inc.
AGrant or award
Stock option (right to buy)derivative
+4,055$0.00$04,055Oct 7, 2025
Sep 30, 2021GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+8$0.00$08Mar 31, 2025
Dec 31, 2021GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+11$0.00$019Mar 31, 2025
Mar 31, 2022GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+25$0.00$044Mar 31, 2025
Jun 30, 2022GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+34$0.00$078Mar 31, 2025
Oct 4, 2022GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+44$0.00$0122Mar 31, 2025
Jan 9, 2023GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+29$0.00$0151Mar 31, 2025
Apr 20, 2023GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+121$0.00$0272Mar 31, 2025
Dec 31, 2023GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+362$0.00$0634Mar 31, 2025
Apr 8, 2024GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+489$0.00$01,123Mar 31, 2025
Nov 14, 2024GCTK
Glucotrack, Inc.
CConversion
Common Stock, par value $0.001 per share
+6,886$31.20$215k8,009Mar 31, 2025
Mar 12, 2025GCTK
Glucotrack, Inc.
XIn-the-money exercise
Common Stock, par value $0.001 per share
+133,532$0.00$0141,541Mar 31, 2025
Mar 26, 2025GCTK
Glucotrack, Inc.
AGrant or award
Common Stock, par value $0.001 per share
+2,076$0.00$0143,617Mar 31, 2025
Jul 18, 2024GCTK
Glucotrack, Inc.
POpen-market purchase
Convertible Promissory Notederivative
-$200,000.00--Mar 31, 2025
Nov 14, 2024GCTK
Glucotrack, Inc.
CConversion
Convertible Promissory Notederivative
-$214,831.00-0Mar 31, 2025
Nov 14, 2024GCTK
Glucotrack, Inc.
AGrant or award
Series A Common Warrantderivative
+6,886--6,886Mar 31, 2025
Nov 14, 2024GCTK
Glucotrack, Inc.
AGrant or award
Series B Common Warrantderivative
+6,886--6,886Mar 31, 2025
Mar 12, 2025GCTK
Glucotrack, Inc.
XIn-the-money exercise
Series B Common Warrantderivative
-6,886$0.00$00Mar 31, 2025

Questions about Luis Malave

Answered from the filings on this page, as of the latest one.

Is Luis Malave buying or selling?

Luis Malave has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.

How did Luis Malave's past buys perform?

Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Luis Malave has 0.

Where does Luis Malave file Form 4?

Luis Malave has filed Form 4 at GCTK (Glucotrack, Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Luis Malave: insider trades and track record | InsiderTell